UPDATE 1-Durect's partner Pfizer to end pain drug deal
March 1 (Reuters) - Specialty pharmaceutical company Durect Corp said its partner Pfizer Inc will terminate their agreement for the development and commercialization of a patch to treat chronic low-back pain.
The patch failed to meet the main goal of a mid-stage trial in April 2011.
Pfizer acquired the rights of the drug, Eladur, through its acquisition of King Pharmaceuticals, which in turn had bought Alpharma Ireland Ltd. In 2008, Alpharma paid Durect an upfront payment of $20 million for Eladur.
Durect shares closed at 72 cents on Thursday on the Nasdaq.
- Colorado baker discriminated by denying gay couple wedding cake: judge
- WTO overcomes last minute hitch to reach its first global trade deal
- Flights delayed as air pollution hits record in Shanghai
- Amish girl in Ohio will not be forced to resume chemo for cancer
- South Africa mourns Mandela, will bury him on December 15 |